{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:31:35Z","timestamp":1788237095132,"version":"build-2803163510"},"reference-count":289,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Peripheral neuropathy comes in all shapes and forms and is a disorder which is found in\nthe peripheral nervous system. It can have an acute or chronic onset depending on the multitude of\npathophysiologic mechanisms involving different parts of nerve fibers. A systematic approach is\nhighly beneficial when it comes to cost-effective diagnosis. More than 30 causes of peripheral neuropathy\nexist ranging from systemic and auto-immune diseases, vitamin deficiencies, viral infections,\ndiabetes, etc. One of the major causes of peripheral neuropathy is drug-induced disease,\nwhich can be split into peripheral neuropathy caused by chemotherapy or by other medications.\nThis review deals with the latest causes of drug-induced peripheral neuropathy, the population involved,\nthe findings on physical examination and various workups needed and how to manage each\ncase.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009621666210720142542","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T19:32:15Z","timestamp":1626895935000},"page":"49-76","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug-Induced Peripheral Neuropathy: Diagnosis and Management"],"prefix":"10.2174","volume":"22","author":[{"given":"Diala","family":"Merheb","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Saint George Hospital University Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgette","family":"Dib","sequence":"additional","affiliation":[{"name":"Department of\nInternal Medicine, Division of Neurology, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroun Bou","family":"Zerdan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University\nof Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara El","family":"Nakib","sequence":"additional","affiliation":[{"name":"Department\nof Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University\nof Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-1869","authenticated-orcid":true,"given":"Saada","family":"Alame","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Clemenceau Medical Center, Faculty of Medical\nSciences, Lebanese University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem I.","family":"Assi","sequence":"additional","affiliation":[{"name":"Department\nof Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University\nof Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"211","volume":"34","author":"Remiche G.","year":"2013","unstructured":"Remiche G.; Kadhim H.; Maris C.; Mavroudakis N.; Peripheral neuropathies, from diagnosis to treatment, review of the literature and lessons from the local experience. Rev Med Brux 2013,34(4),211-220","journal-title":"Rev Med Brux"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12974-017-0831-8","volume":"14","author":"Singh S.","year":"2017","unstructured":"Singh S.; Dallenga T.; Winkler A.; Roemer S.; Maruschak B.; Siebert H.; Br&#xFC;ck W.; Stadelmann C.; Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis. J Neuroinflammation 2017,14(1),57","journal-title":"J Neuroinflammation"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/B978-0-12-802973-2.00015-X","volume":"138","author":"Hanewinckel R.","year":"2016","unstructured":"Hanewinckel R.; Ikram M.; Van Doorn P.;  Handbook of Clinical Neurology 2016,138,263-282","journal-title":"Handbook of Clinical Neurology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00019052-199510000-00001","volume":"8","author":"Hughes R.A.","year":"1995","unstructured":"Hughes R.A.; Epidemiology of peripheral neuropathy. Curr Opin Neurol 1995,8(5),335-338","journal-title":"Curr Opin Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"Seretny M.","year":"2014","unstructured":"Seretny M.; Currie G.L.; Sena E.S.; Ramnarine S.; Grant R.; MacLeod M.R.; Colvin L.A.; Fallon M.; Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014,155(12),2461-2470","journal-title":"Pain"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.12688\/f1000research.21625.1","volume":"9","author":"Gordon-Williams R.","year":"2020","unstructured":"Gordon-Williams R.; Farquhar-Smith P.; Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000 Res 2020,9,9","journal-title":"F1000 Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11910-003-0043-8","volume":"3","author":"Weimer L.H.","year":"2003","unstructured":"Weimer L.H.; Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003,3(1),86-92","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1158\/1078-0432.CCR-08-0169","volume":"14","author":"Morris P.G.","year":"2008","unstructured":"Morris P.G.; Fornier M.N.; Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008,14(22),7167-7172","journal-title":"Clin Cancer Res"},{"key":"ref=9","first-page":"371","volume":"6","author":"Yared J.A.","year":"2012","unstructured":"Yared J.A.; Tkaczuk K.H.; Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 2012,6,371-384","journal-title":"Drug Des Devel Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1023\/A:1008245400251","volume":"8","author":"Hilkens P.H.","year":"1997","unstructured":"Hilkens P.H.; Verweij J.; Vecht C.J.; Stoter G.; van den Bent M.J.; Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997,8(2),187-190","journal-title":"Ann Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4143\/crt.2009.41.4.196","volume":"41","author":"Chon H.J.","year":"2009","unstructured":"Chon H.J.; Rha S.Y.; Im C.K.; Kim C.; Hong M.H.; Kim H.R.; An J.R.; Noh S.H.; Chung H.C.; Jeung H.C.; Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat 2009,41(4),196-204","journal-title":"Cancer Res Treat"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1005805907311","volume":"35","author":"Forsyth P.A.","year":"1997","unstructured":"Forsyth P.A.; Balmaceda C.; Peterson K.; Seidman A.D.; Brasher P.; DeAngelis L.M.; Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997,35(1),47-53","journal-title":"J Neurooncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","volume":"22","author":"Winer E.P.","year":"2004","unstructured":"Winer E.P.; Berry D.A.; Woolf S.; Duggan D.; Kornblith A.; Harris L.N.; Michaelson R.A.; Kirshner J.A.; Fleming G.F.; Perry M.C.; Graham M.L.; Sharp S.A.; Keresztes R.; Henderson I.C.; Hudis C.; Muss H.; Norton L.; Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004,22(11),2061-2068","journal-title":"J Clin Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"Park S.B.","year":"2013","unstructured":"Park S.B.; Goldstein D.; Krishnan A.V.; Lin C.S.Y.; Friedlander M.L.; Cassidy J.; Koltzenburg M.; Kiernan M.C.; Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013,63(6),419-437","journal-title":"CA Cancer J Clin"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3816\/CBC.2007.n.010","volume":"7","author":"Pace A.","year":"2007","unstructured":"Pace A.; Nistic&#xF2; C.; Cuppone F.; Bria E.; Gali&#xE8; E.; Graziano G.; Natoli G.; Sperduti I.; Jandolo B.; Calabretta F.; Tomao S.; Terzoli E.; Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer 2007,7(7),550-554","journal-title":"Clin Breast Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1158\/1078-0432.CCR-12-1590","volume":"18","author":"Baldwin R.M.","year":"2012","unstructured":"Baldwin R.M.; Owzar K.; Zembutsu H.; Chhibber A.; Kubo M.; Jiang C.; Watson D.; Eclov R.J.; Mefford J.; McLeod H.L.; Friedman P.N.; Hudis C.A.; Winer E.P.; Jorgenson E.M.; Witte J.S.; Shulman L.N.; Nakamura Y.; Ratain M.J.; Kroetz D.L.; A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012,18(18),5099-5109","journal-title":"Clin Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/1471-2407-12-355","volume":"12","author":"Ghoreishi Z.","year":"2012","unstructured":"Ghoreishi Z.; Esfahani A.; Djazayeri A.; Djalali M.; Golestan B.; Ayromlou H.; Hashemzade S.; Asghari Jafarabadi M.; Montazeri V.; Keshavarz S.A.; Darabi M.; Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 2012,12(1),355","journal-title":"BMC Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","volume":"60","author":"Chaudhry V.","year":"2003","unstructured":"Chaudhry V.; Chaudhry M.; Crawford T.O.; Simmons-O\u2019Brien E.; Griffin J.W.; Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003,60(2),337-340","journal-title":"Neurology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.critrevonc.2015.04.011","volume":"96","author":"De Iuliis F.","year":"2015","unstructured":"De Iuliis F.; Taglieri L.; Salerno G.; Lanza R.; Scarpa S.; Taxane induced neuropathy in patients affected by breast cancer: Literature review. Crit Rev Oncol Hematol 2015,96(1),34-45","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pain.2004.10.004","volume":"113","author":"McCracken L.M.","year":"2005","unstructured":"McCracken L.M.; Social context and acceptance of chronic pain: the role of solicitous and punishing responses. Pain 2005,113(1-2),155-159","journal-title":"Pain"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/mus.21874","volume":"43","author":"Park S.B.","year":"2011","unstructured":"Park S.B.; Lin C.S.Y.; Krishnan A.V.; Friedlander M.L.; Lewis C.R.; Kiernan M.C.; Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve 2011,43(3),367-374","journal-title":"Muscle Nerve"},{"key":"ref=22","first-page":"204","volume":"4","author":"Tofthagen C.","year":"2013","unstructured":"Tofthagen C.; McAllister R.D.; Visovsky C.; Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J Adv Pract Oncol 2013,4(4),204-215","journal-title":"J Adv Pract Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","volume":"51","author":"Eckhoff L.","year":"2015","unstructured":"Eckhoff L.; Knoop A.; Jensen M.B.; Ewertz M.; Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 2015,51(3),292-300","journal-title":"Eur J Cancer"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1016\/j.jbiomech.2015.07.020","volume":"48","author":"Bober B.G.","year":"2015","unstructured":"Bober B.G.; Shah S.B.; Paclitaxel alters sensory nerve biomechanical properties. J Biomech 2015,48(13),3559-3567","journal-title":"J Biomech"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neuro.2013.05.008","volume":"37","author":"LaPointe N.E.","year":"2013","unstructured":"LaPointe N.E.; Morfini G.; Brady S.T.; Feinstein S.C.; Wilson L.; Jordan M.A.; Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013,37,231-239","journal-title":"Neurotoxicology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-009-0586-0","volume":"119","author":"Shemesh O.A.","year":"2010","unstructured":"Shemesh O.A.; Spira M.E.; Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 2010,119(2),235-248","journal-title":"Acta Neuropathol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.pain.2010.10.030","volume":"152","author":"Boyette-Davis J.","year":"2011","unstructured":"Boyette-Davis J.; Xin W.; Zhang H.; Dougherty P.M.; Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011,152(2),308-313","journal-title":"Pain"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","volume":"20","author":"Zaj\u0105czkowska R.","year":"2019","unstructured":"Zaj\u0105czkowska R.; Kocot-K\u0119pska M.; Leppert W.; Wrzosek A.; Mika J.; Wordliczek J.; Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 2019,20(6),1451","journal-title":"Int J Mol Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1213\/01.ane.0000204318.35194.ed","volume":"102","author":"Siau C.","year":"2006","unstructured":"Siau C.; Bennett G.J.; Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 2006,102(5),1485-1490","journal-title":"Anesth Analg"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/ALN.0000000000000176","volume":"120","author":"Zhang H.","year":"2014","unstructured":"Zhang H.; Dougherty P.M.; Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology 2014,120(6),1463-1475","journal-title":"Anesthesiology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","volume":"2","author":"Areti A.","year":"2014","unstructured":"Areti A.; Yerra V.G.; Naidu V.; Kumar A.; Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol 2014,2,289-295","journal-title":"Redox Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1523\/JNEUROSCI.6343-11.2012","volume":"32","author":"Doyle T.","year":"2012","unstructured":"Doyle T.; Chen Z.; Muscoli C.; Bryant L.; Esposito E.; Cuzzocrea S.; Dagostino C.; Ryerse J.; Rausaria S.; Kamadulski A.; Neumann W.L.; Salvemini D.; Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J Neurosci 2012,32(18),6149-6160","journal-title":"J Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/cyto.2001.0935","volume":"15","author":"Zaks-Zilberman M.","year":"2001","unstructured":"Zaks-Zilberman M.; Zaks T.Z.; Vogel S.N.; Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 2001,15(3),156-165","journal-title":"Cytokine"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"Hershman D.L.","year":"2014","unstructured":"Hershman D.L.; Lacchetti C.; Dworkin R.H.; Lavoie Smith E.M.; Bleeker J.; Cavaletti G.; Chauhan C.; Gavin P.; Lavino A.; Lustberg M.B.; Paice J.; Schneider B.; Smith M.L.; Smith T.; Terstriep S.; Wagner-Johnston N.; Bak K.; Loprinzi C.L.; Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014,32(18),1941-1967","journal-title":"J Clin Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s00520-014-2289-x","volume":"22","author":"Pachman D.R.","year":"2014","unstructured":"Pachman D.R.; Watson J.C.; Lustberg M.B.; Wagner-Johnston N.D.; Chan A.; Broadfield L.; Cheung Y.T.; Steer C.; Storey D.J.; Chandwani K.D.; Paice J.; Jean-Pierre P.; Oh J.; Kamath J.; Fallon M.; Strik H.; Koeppen S.; Loprinzi C.L.; Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer 2014,22(8),2281-2295","journal-title":"Support Care Cancer"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"Smith E.M.L.","year":"2013","unstructured":"Smith E.M.L.; Pang H.; Cirrincione C.; Fleishman S.; Paskett E.D.; Ahles T.; Bressler L.R.; Fadul C.E.; Knox C.; Le-Lindqwister N.; Gilman P.B.; Shapiro C.L.; Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013,309(13),1359-1367","journal-title":"JAMA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.2147\/DDDT.S88023","volume":"9","author":"Kundranda M.N.","year":"2015","unstructured":"Kundranda M.N.; Niu J.; Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 2015,9,3767-3777","journal-title":"Drug Des Devel Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.clbc.2011.03.006","volume":"11","author":"Carlson K.","year":"2011","unstructured":"Carlson K.; Ocean A.J.; Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011,11(2),73-81","journal-title":"Clin Breast Cancer"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"Gradishar W.J.","year":"2006","unstructured":"Gradishar W.J.; Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006,7(8),1041-1053","journal-title":"Expert Opin Pharmacother"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/sleep\/26.8.1038","volume":"26","author":"Desai A.V.","year":"2003","unstructured":"Desai A.V.; Marks G.; Grunstein R.; Does sleep deprivation worsen mild obstructive sleep apnea? Sleep 2003,26(8),1038-1041","journal-title":"Sleep"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/jcb.20091","volume":"92","author":"Framson P.E.","year":"2004","unstructured":"Framson P.E.; Sage E.H.; SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004,92(4),679-690","journal-title":"J Cell Biochem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1073\/pnas.91.8.3448","volume":"91","author":"Goldblum S.E.","year":"1994","unstructured":"Goldblum S.E.; Ding X.; Funk S.E.; Sage E.H.; SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc Natl Acad Sci USA 1994,91(8),3448-3452","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=43","author":"Trieu V.","year":"2005","unstructured":"Trieu V.; Frankel T.; Labao E.; Soon-Shiong P.; Desai N.;  SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol 2005","journal-title":"SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"L187","DOI":"10.1152\/ajplung.00152.2002","volume":"284","author":"John T.A.","year":"2003","unstructured":"John T.A.; Vogel S.M.; Tiruppathi C.; Malik A.B.; Minshall R.D.; Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003,284(1),L187-L196","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"Gradishar W.J.","year":"2005","unstructured":"Gradishar W.J.; Tjulandin S.; Davidson N.; Shaw H.; Desai N.; Bhar P.; Hawkins M.; O\u2019Shaughnessy J.; Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005,23(31),7794-7803","journal-title":"J Clin Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e12407","DOI":"10.1111\/ecc.12407","volume":"26","author":"Peng L.","year":"2017","unstructured":"Peng L.; Bu Z.; Ye X.; Zhou Y.; Zhao Q.; Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl) 2017,26(5),e12407","journal-title":"Eur J Cancer Care (Engl)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","volume":"139","author":"Guo X.","year":"2019","unstructured":"Guo X.; Sun H.; Dong J.; Feng Y.; Li H.; Zhuang R.; Wang P.; Cai W.; Zhou Y.; Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol 2019,139,16-23","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","volume":"24","author":"Lee J.J.","year":"2006","unstructured":"Lee J.J.; Swain S.M.; Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006,24(10),1633-1642","journal-title":"J Clin Oncol"},{"key":"ref=49","first-page":"455","volume":"6","author":"Swain S.M.","year":"2008","unstructured":"Swain S.M.; Arezzo J.C.; Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008,6(6),455-467","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1254\/jphs.11062SC","volume":"117","author":"Yamashita Y.","year":"2011","unstructured":"Yamashita Y.; Egashira N.; Masuguchi K.; Ushio S.; Kawashiri T.; Oishi R.; Comparison of peripheral neuropathy induced by standard and nanoparticle albumin-bound paclitaxel in rats. J Pharmacol Sci 2011,117(2),116-120","journal-title":"J Pharmacol Sci"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/843019","author":"Amptoulach S","year":"2011","unstructured":"Amptoulach S; Tsavaris N.; Neurotoxicity caused by the treatment with platinum analogues. Chemotherapy Research and Practice 2011","journal-title":"Chemotherapy Research and Practice"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001113220210","author":"Mollman J.E.","year":"1990","unstructured":"Mollman J.E.;  Cisplatin neurotoxicity 1990","journal-title":"Cisplatin neurotoxicity"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0305-7372(79)80057-2","volume":"6","author":"Prestayko A.W.","year":"1979","unstructured":"Prestayko A.W.; D\u2019Aoust J.C.; Issell B.F.; Crooke S.T.; Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 1979,6(1),17-39","journal-title":"Cancer Treat Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1634\/theoncologist.2014-0044","volume":"20","author":"Avan A.","year":"2015","unstructured":"Avan A.; Postma T.J.; Ceresa C.; Avan A.; Cavaletti G.; Giovannetti E.; Peters G.J.; Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist 2015,20(4),411-432","journal-title":"Oncologist"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005228.pub4","author":"Albers JW","year":"2014","unstructured":"Albers JW; Chaudhry V; Cavaletti G; Donehower RC; Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews 2014(3)","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","volume":"10","author":"Starobova H.","year":"2017","unstructured":"Starobova H.; Vetter I.; Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 2017,10,174","journal-title":"Front Mol Neurosci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","volume":"82","author":"Argyriou A.A.","year":"2012","unstructured":"Argyriou A.A.; Bruna J.; Marmiroli P.; Cavaletti G.; Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012,82(1),51-77","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/jns5.12073","volume":"19","author":"Cavaletti G.","year":"2014","unstructured":"Cavaletti G.; Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know. J Peripher Nerv Syst 2014,19(2),66-76","journal-title":"J Peripher Nerv Syst"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/1440-1681.12088","volume":"40","author":"Ip V.","year":"2013","unstructured":"Ip V.; Liu J.J.; McKeage M.J.; Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. Clin Exp Pharmacol Physiol 2013,40(6),371-378","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bcp.2012.10.023","volume":"85","author":"Liu J.J.","year":"2013","unstructured":"Liu J.J.; Kim Y.; Yan F.; Ding Q.; Ip V.; Jong N.N.; Mercer J.F.; McKeage M.J.; Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem Pharmacol 2013,85(2),207-215","journal-title":"Biochem Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2004.09.007","volume":"53","author":"Safaei R.","year":"2005","unstructured":"Safaei R.; Howell S.B.; Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005,53(1),13-23","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"12195","DOI":"10.1021\/jp0518916","volume":"109","author":"Zhu C.","year":"2005","unstructured":"Zhu C.; Raber J.; Eriksson L.A.; Hydrolysis process of the second generation platinum-based anticancer drug cis-amminedichlorocyclohexylamineplatinum(II). J Phys Chem B 2005,109(24),12195-12205","journal-title":"J Phys Chem B"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/nar\/gkm032","volume":"35","author":"Chv&#xE1;lov&#xE1; K.","year":"2007","unstructured":"Chv&#xE1;lov&#xE1; K.; Brabec V.; Kasp&#xE1;rkov&#xE1; J.; Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 2007,35(6),1812-1821","journal-title":"Nucleic Acids Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.nbd.2004.09.013","volume":"18","author":"McDonald E.S.","year":"2005","unstructured":"McDonald E.S.; Randon K.R.; Knight A.; Windebank A.J.; Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005,18(2),305-313","journal-title":"Neurobiol Dis"},{"key":"ref=65","first-page":"883","volume":"20","author":"Meijer C.","year":"1999","unstructured":"Meijer C.; de Vries E.G.; Marmiroli P.; Tredici G.; Frattola L.; Cavaletti G.; Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999,20(6),883-887","journal-title":"Neurotoxicology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.1523\/JNEUROSCI.0523-07.2007","volume":"27","author":"Dzagnidze A.","year":"2007","unstructured":"Dzagnidze A.; Katsarava Z.; Makhalova J.; Liedert B.; Yoon M-S.; Kaube H.; Limmroth V.; Thomale J.; Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007,27(35),9451-9457","journal-title":"J Neurosci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.neuro.2006.04.010","volume":"27","author":"Ta L.E.","year":"2006","unstructured":"Ta L.E.; Espeset L.; Podratz J.; Windebank A.J.; Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006,27(6),992-1002","journal-title":"Neurotoxicology"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","volume":"8","author":"McWhinney S.R.","year":"2009","unstructured":"McWhinney S.R.; Goldberg R.M.; McLeod H.L.; Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009,8(1),10-16","journal-title":"Mol Cancer Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","volume":"34","author":"Argyriou A.A.","year":"2008","unstructured":"Argyriou A.A.; Polychronopoulos P.; Iconomou G.; Chroni E.; Kalofonos H.P.; A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008,34(4),368-377","journal-title":"Cancer Treat Rev"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","volume":"18","author":"Neijt J.P.","year":"2000","unstructured":"Neijt J.P.; Engelholm S.A.; Tuxen M.K.; S&#xF8;rensen P.G.; Hansen M.; Sessa C.; de Swart C.A.; Hirsch F.R.; Lund B.; van Houwelingen H.C.; Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000,18(17),3084-3092","journal-title":"J Clin Oncol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"Parmar M.K.","year":"2003","unstructured":"Parmar M.K.; Ledermann J.A.; Colombo N.; du Bois A.; Delaloye J.F.; Kristensen G.B.; Wheeler S.; Swart A.M.; Qian W.; Torri V.; Floriani I.; Jayson G.; Lamont A.; Trop&#xE9; C.; Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 2003,361(9375),2099-2106","journal-title":"Lancet"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0305-7372(85)90027-1","volume":"12","author":"Canetta R.","year":"1985","unstructured":"Canetta R.; Rozencweig M.; Carter S.K.; Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985,12(Suppl. A),125-136","journal-title":"Cancer Treat Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e106485","DOI":"10.1371\/journal.pone.0106485","volume":"9","author":"Kelley M.R.","year":"2014","unstructured":"Kelley M.R.; Jiang Y.; Guo C.; Reed A.; Meng H.; Vasko M.R.; Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS One 2014,9(9),e106485","journal-title":"PLoS One"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/toxics3030304","volume":"3","author":"Chiorazzi A.","year":"2015","unstructured":"Chiorazzi A.; Semperboni S.; Marmiroli P.; Current view in platinum drug mechanisms of peripheral neurotoxicity. Toxics 2015,3(3),304-321","journal-title":"Toxics"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1579-2129(07)60086-X","volume":"43","author":"de Cos Escu&#xED;n JS","year":"2007","unstructured":"de Cos Escu&#xED;n JS; Delgado IU; Rodr&#xED;guez JC; L&#xF3;pez MJ; Vicente CD; Miranda JAR; Stage IIIA and IIIB non-small cell lung cancer: results of chemotherapy combined with radiation therapy and analysis of prognostic factors. Archivos de Bronconeumolog&#xED;a ((English Edition)) 2007,43(7),358-365","journal-title":"Archivos de Bronconeumolog&#xED;a ((English Edition))"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/sj.bjc.6603869","volume":"97","author":"Helbekkmo N.","year":"2007","unstructured":"Helbekkmo N.; Sundstr&#xF8;m S.H.; Aaseb&#xF8; U.; Brunsvig P.F.; von Plessen C.; Hjelde H.H.; Garpestad O.K.; Bailey A.; Bremnes R.M.; Vinorelbine\/carboplatin vs gemcitabine\/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007,97(3),283-289","journal-title":"Br J Cancer"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/jnnp.64.5.667","volume":"64","author":"Heinzlef O.","year":"1998","unstructured":"Heinzlef O.; Lotz J-P.; Roullet E.; Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998,64(5),667-669","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=78","author":"Ozols R.F.","year":"1985","unstructured":"Ozols R.F.; Young R.C.;  Seminars in oncology 1985","journal-title":"Seminars in oncology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1212\/WNL.34.7.934","volume":"34","author":"Roelofs R.I.","year":"1984","unstructured":"Roelofs R.I.; Hrushesky W.; Rogin J.; Rosenberg L.; Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984,34(7),934-938","journal-title":"Neurology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9","volume":"54","author":"Thompson S.W.","year":"1984","unstructured":"Thompson S.W.; Davis L.E.; Kornfeld M.; Hilgers R.D.; Standefer J.C.; Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984,54(7),1269-1275","journal-title":"Cancer"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/brain\/awl356","volume":"130","author":"Krarup-Hansen A.","year":"2007","unstructured":"Krarup-Hansen A.; Helweg-Larsen S.; Schmalbruch H.; R&#xF8;rth M.; Krarup C.; Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007,130(Pt 4),1076-1088","journal-title":"Brain"},{"key":"ref=82","first-page":"1527","volume":"63","author":"Von Hoff D.D.","year":"1979","unstructured":"Von Hoff D.D.; Schilsky R.; Reichert C.M.; Reddick R.L.; Rozencweig M.; Young R.C.; Muggia F.M.; Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979,63(9-10),1527-1531","journal-title":"Cancer Treat Rep"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/1097-0142(19900915)66:6<1117::AID-CNCR2820660607>3.0.CO;2-O","volume":"66","author":"Siegal T.","year":"1990","unstructured":"Siegal T.; Haim N.; Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990,66(6),1117-1123","journal-title":"Cancer"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/cncr.27732","volume":"119","author":"Argyriou A.A.","year":"2013","unstructured":"Argyriou A.A.; Cavaletti G.; Briani C.; Velasco R.; Bruna J.; Campagnolo M.; Alberti P.; Bergamo F.; Cortinovis D.; Cazzaniga M.; Santos C.; Papadimitriou K.; Kalofonos H.P.; Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 2013,119(2),438-444","journal-title":"Cancer"},{"key":"ref=85","author":"Extra J-M.","year":"1998","unstructured":"Extra J-M.; Marty M.; Brienza S.; Misset J-L.;  Seminars in oncology 1998","journal-title":"Seminars in oncology"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0305-7372(89)90041-8","volume":"16","author":"Cersosimo R.J.","year":"1989","unstructured":"Cersosimo R.J.; Cisplatin neurotoxicity. Cancer Treat Rev 1989,16(4),195-211","journal-title":"Cancer Treat Rev"},{"key":"ref=87","author":"Gamelin E.","year":"2002","unstructured":"Gamelin E.; Gamelin L.; Bossi L.; Quasthoff S.;  Seminars in oncology 2002","journal-title":"Seminars in oncology"},{"key":"ref=88","author":"Cassidy J.","year":"2002","unstructured":"Cassidy J.; Misset J-L.;  Oxaliplatin-related side effects: characteristics and management Seminars in oncology 2002","journal-title":"Oxaliplatin-related side effects: characteristics and management Seminars in oncology"},{"key":"ref=89","first-page":"249","volume":"1","author":"Saif M.W.","year":"2005","unstructured":"Saif M.W.; Reardon J.; Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005,1(4),249-258","journal-title":"Ther Clin Risk Manag"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(11)70131-0","volume":"12","author":"Cavaletti G.","year":"2011","unstructured":"Cavaletti G.; Alberti P.; Marmiroli P.; Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011,12(12),1151-1161","journal-title":"Lancet Oncol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/COC.0b013e318246b50d","volume":"36","author":"Alejandro L.M.","year":"2013","unstructured":"Alejandro L.M.; Behrendt C.E.; Chen K.; Openshaw H.; Shibata S.; Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 2013,36(4),331-337","journal-title":"Am J Clin Oncol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdt409","volume":"25","author":"Alberti P.","year":"2014","unstructured":"Alberti P.; Rossi E.; Cornblath D.R.; Merkies I.S.; Postma T.J.; Frigeni B.; Bruna J.; Velasco R.; Argyriou A.A.; Kalofonos H.P.; Psimaras D.; Ricard D.; Pace A.; Gali&#xE8; E.; Briani C.; Dalla Torre C.; Faber C.G.; Lalisang R.I.; Boogerd W.; Brandsma D.; Koeppen S.; Hense J.; Storey D.; Kerrigan S.; Schenone A.; Fabbri S.; Valsecchi M.G.; Cavaletti G.; Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 2014,25(1),257-264","journal-title":"Ann Oncol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1188\/16.CJON.20-01AP","volume":"20","author":"Curcio K.R.","year":"2016","unstructured":"Curcio K.R.; Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature. Clin J Oncol Nurs 2016,20(2),144-151","journal-title":"Clin J Oncol Nurs"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5306\/wjco.v8.i4.329","volume":"8","author":"Kanat O.","year":"2017","unstructured":"Kanat O.; Ertas H.; Caner B.; Platinum-induced neurotoxicity: A review of possible mechanisms. World J Clin Oncol 2017,8(4),329-335","journal-title":"World J Clin Oncol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10147-011-0298-z","volume":"17","author":"Inoue N.","year":"2012","unstructured":"Inoue N.; Ishida H.; Sano M.; Kishino T.; Okada N.; Kumamoto K.; Ishibashi K.; Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol 2012,17(4),341-347","journal-title":"Int J Clin Oncol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","volume":"63","author":"Verstappen C.C.","year":"2003","unstructured":"Verstappen C.C.; Heimans J.J.; Hoekman K.; Postma T.J.; Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003,63(15),1549-1563","journal-title":"Drugs"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/1471-2407-10-451","volume":"10","author":"Hill A.","year":"2010","unstructured":"Hill A.; Bergin P.; Hanning F.; Thompson P.; Findlay M.; Damianovich D.; McKeage M.J.; Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer 2010,10(1),451","journal-title":"BMC Cancer"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1093\/brain\/awp219","volume":"132","author":"Park S.B.","year":"2009","unstructured":"Park S.B.; Lin C.S-Y.; Krishnan A.V.; Goldstein D.; Friedlander M.L.; Kiernan M.C.; Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009,132(Pt 10),2712-2723","journal-title":"Brain"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.12659\/MSM.893142","volume":"21","author":"Yang L.","year":"2015","unstructured":"Yang L.; Yu L.; Chen X.; Hu Y.; Wang B.; Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia. Med Sci Monit 2015,21,1656-1661","journal-title":"Med Sci Monit"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1040-8428(98)00023-7","volume":"29","author":"Gidding C.E.","year":"1999","unstructured":"Gidding C.E.; Kellie S.J.; Kamps W.A.; de Graaf S.S.; Vincristine revisited. Crit Rev Oncol Hematol 1999,29(3),267-287","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1158\/1535-7163.MCT-09-0679","volume":"9","author":"Gan P.P.","year":"2010","unstructured":"Gan P.P.; McCarroll J.A.; Po\u2019uha S.T.; Kamath K.; Jordan M.A.; Kavallaris M.; Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther 2010,9(5),1339-1348","journal-title":"Mol Cancer Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41397-017-0003-3","volume":"18","author":"Gutierrez-Camino &#xC1;.","year":"2018","unstructured":"Gutierrez-Camino &#xC1;.; Umerez M.; Martin-Guerrero I.; Garc&#xED;a de Andoin N.; Santos B.; Sastre A.; Echebarria-Barona A.; Astigarraga I.; Navajas A.; Garcia-Orad A.; Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J 2018,18(6),704-712","journal-title":"Pharmacogenomics J"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/neu.480110304","volume":"11","author":"Chan S.Y.","year":"1980","unstructured":"Chan S.Y.; Worth R.; Ochs S.; Block of axoplasmic transport in vitro by vinca alkaloids. J Neurobiol 1980,11(3),251-264","journal-title":"J Neurobiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jpain.2005.09.006","volume":"7","author":"Devor M.","year":"2006","unstructured":"Devor M.; Sodium channels and mechanisms of neuropathic pain. J Pain 2006,7(1)(Suppl. 1),S3-S12","journal-title":"J Pain"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1038\/srep06370","volume":"4","author":"Boehmerle W.","year":"2014","unstructured":"Boehmerle W.; Huehnchen P.; Peruzzaro S.; Balkaya M.; Endres M.; Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl\/6 mice. Sci Rep 2014,4,6370","journal-title":"Sci Rep"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","volume":"596","author":"Carozzi V.A.","year":"2015","unstructured":"Carozzi V.A.; Canta A.; Chiorazzi A.; Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 2015,596,90-107","journal-title":"Neurosci Lett"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/jns.12114","volume":"20","author":"Lavoie Smith E.M.","year":"2015","unstructured":"Lavoie Smith E.M.; Li L.; Chiang C.; Thomas K.; Hutchinson R.J.; Wells E.M.; Ho R.H.; Skiles J.; Chakraborty A.; Bridges C.M.; Renbarger J.; Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst 2015,20(1),37-46","journal-title":"J Peripher Nerv Syst"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MPH.0000000000000825","volume":"39","author":"Kavcic M.","year":"2017","unstructured":"Kavcic M.; Koritnik B.; Krzan M.; Velikonja O.; Prelog T.; Stefanovic M.; Debeljak M.; Jazbec J.; Electrophysiological studies to detect peripheral neuropathy in children treated with vincristine. J Pediatr Hematol Oncol 2017,39(4),266-271","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","volume":"73","author":"Haim N.","year":"1994","unstructured":"Haim N.; Epelbaum R.; Ben-Shahar M.; Yarnitsky D.; Simri W.; Robinson E.; Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994,73(10),2515-2519","journal-title":"Cancer"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","volume":"19","author":"Barton D.L.","year":"2011","unstructured":"Barton D.L.; Wos E.J.; Qin R.; Mattar B.I.; Green N.B.; Lanier K.S.; Bearden J.D.; Kugler J.W.; Hoff K.L.; Reddy P.S.; Rowland K.M.; Riepl M.; Christensen B.; Loprinzi C.L.; A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011,19(6),833-841","journal-title":"Support Care Cancer"},{"key":"ref=111","first-page":"2416","volume":"6","author":"Mora E.","year":"2016","unstructured":"Mora E.; Smith E.M.L.; Donohoe C.; Hertz D.L.; Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res 2016,6(11),2416-2430","journal-title":"Am J Cancer Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.mph.0000165130.21539.a3","volume":"27","author":"El Hayek M.","year":"2005","unstructured":"El Hayek M.; Trad O.; Jamil A.; Vincristine-induced urinary bladder paralysis. J Pediatr Hematol Oncol 2005,27(5),286-287","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0962-8924(98)01346-4","volume":"8","author":"Lee D.H.","year":"1998","unstructured":"Lee D.H.; Goldberg A.L.; Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998,8(10),397-403","journal-title":"Trends Cell Biol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","volume":"51","author":"Moreau P.","year":"2012","unstructured":"Moreau P.; Karamanesht I.I.; Domnikova N.; Kyselyova M.Y.; Vilchevska K.V.; Doronin V.A.; Schmidt A.; Hulin C.; Leleu X.; Esseltine D.L.; Venkatakrishnan K.; Skee D.; Feng H.; Girgis S.; Cakana A.; van de Velde H.; Deraedt W.; Facon T.; Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012,51(12),823-829","journal-title":"Clin Pharmacokinet"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","volume":"11","author":"Delforge M.","year":"2010","unstructured":"Delforge M.; Blad&#xE9; J.; Dimopoulos M.A.; Facon T.; Kropff M.; Ludwig H.; Palumbo A.; Van Damme P.; San-Miguel J.F.; Sonneveld P.; Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010,11(11),1086-1095","journal-title":"Lancet Oncol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","volume":"66","author":"Crawford L.J.","year":"2006","unstructured":"Crawford L.J.; Walker B.; Ovaa H.; Chauhan D.; Anderson K.C.; Morris T.C.; Irvine A.E.; Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006,66(12),6379-6386","journal-title":"Cancer Res"},{"key":"ref=117","first-page":"165","volume":"69","author":"\u0141uczkowska K.","year":"2018","unstructured":"\u0141uczkowska K.; Litwi\u0144ska Z.; Paczkowska E.; Machali\u0144ski B.; Pathophysiology of drug-induced peripheral neuropathy in multiple myeloma patients. J Physiol Pharmacol 2018,69,165-172","journal-title":"J Physiol Pharmacol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","volume":"103","author":"Kaplan G.S.","year":"2017","unstructured":"Kaplan G.S.; Torcun C.C.; Grune T.; Ozer N.K.; Karademir B.; Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect. Free Radic Biol Med 2017,103,1-13","journal-title":"Free Radic Biol Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1529-8027.2010.00248.x","volume":"15","author":"Velasco R.","year":"2010","unstructured":"Velasco R.; Petit J.; Clap&#xE9;s V.; Verd&#xFA; E.; Navarro X.; Bruna J.; Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010,15(1),17-25","journal-title":"J Peripher Nerv Syst"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.clml.2017.06.035","volume":"17","author":"Lakshman A","year":"2017","unstructured":"Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4. 0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction. Clinical Lymphoma Myeloma and Leukemia 2017,17(8),513-519","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","volume":"65","author":"Landowski T.H.","year":"2005","unstructured":"Landowski T.H.; Megli C.J.; Nullmeyer K.D.; Lynch R.M.; Dorr R.T.; Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005,65(9),3828-3836","journal-title":"Cancer Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","volume":"114","author":"Hideshima T.","year":"2009","unstructured":"Hideshima T.; Ikeda H.; Chauhan D.; Okawa Y.; Raje N.; Podar K.; Mitsiades C.; Munshi N.C.; Richardson P.G.; Carrasco R.D.; Anderson K.C.; Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009,114(5),1046-1052","journal-title":"Blood"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/bjh.12624","volume":"164","author":"Azoulay D.","year":"2014","unstructured":"Azoulay D.; Lavie D.; Horowitz N.; Suriu C.; Gatt M.E.; Akria L.; Perlman R.; Braester A.; Ben-Yehuda D.; Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol 2014,164(3),454-456","journal-title":"Br J Haematol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","volume":"11","author":"Broyl A.","year":"2010","unstructured":"Broyl A.; Corthals S.L.; Jongen J.L.; van der Holt B.; Kuiper R.; de Knegt Y.; van Duin M.; el Jarari L.; Bertsch U.; Lokhorst H.M.; Durie B.G.; Goldschmidt H.; Sonneveld P.; Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial. Lancet Oncol 2010,11(11),1057-1065","journal-title":"Lancet Oncol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","volume":"14","author":"Meregalli C.","year":"2010","unstructured":"Meregalli C.; Canta A.; Carozzi V.A.; Chiorazzi A.; Oggioni N.; Gilardini A.; Ceresa C.; Avezza F.; Crippa L.; Marmiroli P.; Cavaletti G.; Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010,14(4),343-350","journal-title":"Eur J Pain"},{"key":"ref=126","first-page":"151","volume":"5","author":"Meregalli C.","year":"2012","unstructured":"Meregalli C.; Ceresa C.; Canta A.; Carozzi V.A.; Chiorazzi A.; Sala B.; Oggioni N.; Lanza M.; Letari O.; Ferrari F.; Avezza F.; Marmiroli P.; Caselli G.; Cavaletti G.; CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res 2012,5,151-167","journal-title":"J Pain Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12640-009-9086-1","volume":"17","author":"Casafont I.","year":"2010","unstructured":"Casafont I.; Berciano M.T.; Lafarga M.; Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 2010,17(2),167-178","journal-title":"Neurotox Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","volume":"204","author":"Cavaletti G.","year":"2007","unstructured":"Cavaletti G.; Gilardini A.; Canta A.; Rigamonti L.; Rodriguez-Menendez V.; Ceresa C.; Marmiroli P.; Bossi M.; Oggioni N.; D\u2019Incalci M.; De Coster R.; Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007,204(1),317-325","journal-title":"Exp Neurol"},{"key":"ref=129","author":"Meregalli C.","year":"2009","unstructured":"Meregalli C.; Canta A.; Chiorazzi A.; Gilardini A.; RODRIGUEZ MENENDEZ V Annual Meeting of the Peripheral-Nerve-Society 2009","journal-title":"Annual Meeting of the Peripheral-Nerve-Society"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","volume":"119","author":"Ravaglia S.","year":"2008","unstructured":"Ravaglia S.; Corso A.; Piccolo G.; Lozza A.; Alfonsi E.; Mangiacavalli S.; Varettoni M.; Zappasodi P.; Moglia A.; Lazzarino M.; Costa A.; Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008,119(11),2507-2512","journal-title":"Clin Neurophysiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2011.10.019","volume":"291","author":"Jaggi A.S.","year":"2012","unstructured":"Jaggi A.S.; Singh N.; Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012,291(1-3),1-9","journal-title":"Toxicology"},{"key":"ref=132","first-page":"107","volume":"32","author":"Wang H","year":"2011","unstructured":"Wang H; Liu Z; Yang W; Liao A; Zhang R; Wu B; Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione. Zhonghua xue ye xue za zhi= Zhonghua xueyexue zazhi 2011,32(2),107-111","journal-title":"Zhonghua xue ye xue za zhi= Zhonghua xueyexue zazhi"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","volume":"15","author":"Dick L.R.","year":"2010","unstructured":"Dick L.R.; Fleming P.E.; Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010,15(5-6),243-249","journal-title":"Drug Discov Today"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1529-8027.2010.00287.x","volume":"15","author":"Saifee T.A.","year":"2010","unstructured":"Saifee T.A.; Elliott K.J.; Rabin N.; Yong K.L.; D\u2019Sa S.; Brandner S.; Lunn M.P.; Blake J.; Reilly M.M.; Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst 2010,15(4),366-368","journal-title":"J Peripher Nerv Syst"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CND.0000000000000077","volume":"16","author":"Thawani S.P.","year":"2015","unstructured":"Thawani S.P.; Tanji K.; De Sousa E.A.; Weimer L.H.; Brannagan T.H.; Bortezomib-associated demyelinating neuropathy--clinical and pathologic features. J Clin Neuromuscul Dis 2015,16(4),202-209","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","volume":"13","author":"Windebank A.J.","year":"2008","unstructured":"Windebank A.J.; Grisold W.; Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008,13(1),27-46","journal-title":"J Peripher Nerv Syst"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","volume":"88","author":"Argyriou A.A.","year":"2014","unstructured":"Argyriou A.A.; Cavaletti G.; Bruna J.; Kyritsis A.P.; Kalofonos H.P.; Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol 2014,88(9),1669-1679","journal-title":"Arch Toxicol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1529-8027.2008.00192.x","volume":"13","author":"Lanzani F.","year":"2008","unstructured":"Lanzani F.; Mattavelli L.; Frigeni B.; Rossini F.; Cammarota S.; Petr&#xF2; D.; Jann S.; Cavaletti G.; Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 2008,13(4),267-274","journal-title":"J Peripher Nerv Syst"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10286-012-0164-8","volume":"22","author":"Stratogianni A.","year":"2012","unstructured":"Stratogianni A.; Tosch M.; Schlemmer H.; Weis J.; Katona I.; Isenmann S.; Haensch C.A.; Bortezomib-induced severe autonomic neuropathy. Clin Auton Res 2012,22(4),199-202","journal-title":"Clin Auton Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10072-010-0475-2","volume":"32","author":"Giannoccaro M.P.","year":"2011","unstructured":"Giannoccaro M.P.; Donadio V.; Gomis P&#xE8;rez C.; Borsini W.; Di Stasi V.; Liguori R.; Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurol Sci 2011,32(2),361-363","journal-title":"Neurol Sci"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FPC.0b013e3283436b45","volume":"21","author":"Favis R.","year":"2011","unstructured":"Favis R.; Sun Y.; van de Velde H.; Broderick E.; Levey L.; Meyers M.; Mulligan G.; Harousseau J.L.; Richardson P.G.; Ricci D.S.; Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 2011,21(3),121-129","journal-title":"Pharmacogenet Genomics"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3324\/haematol.2011.041434","volume":"96","author":"Corthals S.L.","year":"2011","unstructured":"Corthals S.L.; Kuiper R.; Johnson D.C.; Sonneveld P.; Hajek R.; van der Holt B.; Magrangeas F.; Goldschmidt H.; Morgan G.J.; Avet-Loiseau H.; Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011,96(11),1728-1732","journal-title":"Haematologica"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22921","volume":"110","author":"Badros A.","year":"2007","unstructured":"Badros A.; Goloubeva O.; Dalal J.S.; Can I.; Thompson J.; Rapoport A.P.; Heyman M.; Akpek G.; Fenton R.G.; Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007,110(5),1042-1049","journal-title":"Cancer"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/cncr.27463","volume":"118","author":"Stubblefield M.D.","year":"2012","unstructured":"Stubblefield M.D.; McNeely M.L.; Alfano C.M.; Mayer D.K.; A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer 2012,118(8)(Suppl.),2250-2260","journal-title":"Cancer"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/CAD.0b013e32833db89d","volume":"21","author":"Kanbayashi Y.","year":"2010","unstructured":"Kanbayashi Y.; Hosokawa T.; Okamoto K.; Konishi H.; Otsuji E.; Yoshikawa T.; Takagi T.; Taniwaki M.; Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs 2010,21(9),877-881","journal-title":"Anticancer Drugs"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.7314\/APJCP.2015.16.5.2093","volume":"16","author":"Wang L.","year":"2015","unstructured":"Wang L.; Wang K-F.; Chang B-Y.; Chen X-Q.; Xia Z-J.; Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac J Cancer Prev 2015,16(5),2093-2098","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"Richardson P.G.","year":"2009","unstructured":"Richardson P.G.; Xie W.; Mitsiades C.; Chanan-Khan A.A.; Lonial S.; Hassoun H.; Avigan D.E.; Oaklander A.L.; Kuter D.J.; Wen P.Y.; Kesari S.; Briemberg H.R.; Schlossman R.L.; Munshi N.C.; Heffner L.T.; Doss D.; Esseltine D.L.; Weller E.; Anderson K.C.; Amato A.A.; Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009,27(21),3518-3525","journal-title":"J Clin Oncol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"Argyriou A.A.","year":"2008","unstructured":"Argyriou A.A.; Iconomou G.; Kalofonos H.P.; Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008,112(5),1593-1599","journal-title":"Blood"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"Oken M.M.","year":"1982","unstructured":"Oken M.M.; Creech R.H.; Tormey D.C.; Horton J.; Davis T.E.; McFadden E.T.; Carbone P.P.; Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982,5(6),649-655","journal-title":"Am J Clin Oncol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/07357909009017560","volume":"8","author":"Ajani J.A.","year":"1990","unstructured":"Ajani J.A.; Welch S.R.; Raber M.N.; Fields W.S.; Krakoff I.H.; Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990,8(2),147-159","journal-title":"Cancer Invest"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"Miller A","year":"1981","unstructured":"Miller A; Hoogstraten B; Staquet M; Winkler A; Reporting results of cancer treatment. cancer 1981,47(1),207-214","journal-title":"cancer"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/toxics3030322","volume":"3","author":"Nicolini G.","year":"2015","unstructured":"Nicolini G.; Monfrini M.; Scuteri A.; Axonal transport impairment in chemotherapy-induced peripheral neuropathy. Toxics 2015,3(3),322-341","journal-title":"Toxics"},{"key":"ref=153","author":"Lee J.J.","year":"2005","unstructured":"Lee J.J.; Swain S.M.;  Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR) Seminars in oncology 2005","journal-title":"Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR) Seminars in oncology"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.clinthera.2008.09.015","volume":"30","author":"Steinberg M.","year":"2008","unstructured":"Steinberg M.; Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Clin Ther 2008,30(9),1590-1617","journal-title":"Clin Ther"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1158\/0008-5472.CAN-08-0237","volume":"68","author":"Hoffmann J.","year":"2008","unstructured":"Hoffmann J.; Vitale I.; Buchmann B.; Galluzzi L.; Schwede W.; Senovilla L.; Skuballa W.; Vivet S.; Lichtner R.B.; Vicencio J.M.; Panaretakis T.; Siemeister G.; Lage H.; Nanty L.; Hammer S.; Mittelstaedt K.; Winsel S.; Eschenbrenner J.; Castedo M.; Demarche C.; Klar U.; Kroemer G.; Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008,68(13),5301-5308","journal-title":"Cancer Res"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.1002\/anie.200602785","volume":"45","author":"Klar U.","year":"2006","unstructured":"Klar U.; Buchmann B.; Schwede W.; Skuballa W.; Hoffmann J.; Lichtner R.B.; Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006,45(47),7942-7948","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jpainsymman.2011.02.022","volume":"42","author":"Argyriou A.A.","year":"2011","unstructured":"Argyriou A.A.; Marmiroli P.; Cavaletti G.; Kalofonos H.P.; Epothilone-induced peripheral neuropathy: a review of current knowledge. J Pain Symptom Manage 2011,42(6),931-940","journal-title":"J Pain Symptom Manage"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/s00520-012-1384-0","volume":"20","author":"Vahdat L.T.","year":"2012","unstructured":"Vahdat L.T.; Thomas E.S.; Roch&#xE9; H.H.; Hortobagyi G.N.; Sparano J.A.; Yelle L.; Fornier M.N.; Mart&#xED;n M.; Bunnell C.A.; Mukhopadhyay P.; Peck R.A.; Perez E.A.; Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 2012,20(11),2661-2668","journal-title":"Support Care Cancer"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","volume":"6","author":"Cavaletti G.","year":"2010","unstructured":"Cavaletti G.; Marmiroli P.; Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010,6(12),657-666","journal-title":"Nat Rev Neurol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11910-017-0757-7","volume":"17","author":"Cioroiu C.","year":"2017","unstructured":"Cioroiu C.; Weimer L.H.; Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2017,17(6),47","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"Cortes J.","year":"2011","unstructured":"Cortes J.; O\u2019Shaughnessy J.; Loesch D.; Blum J.L.; Vahdat L.T.; Petrakova K.; Chollet P.; Manikas A.; Di&#xE9;ras V.; Delozier T.; Vladimirov V.; Cardoso F.; Koh H.; Bougnoux P.; Dutcus C.E.; Seegobin S.; Mir D.; Meneses N.; Wanders J.; Twelves C.; Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011,377(9769),914-923","journal-title":"Lancet"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"Twelves C.","year":"2014","unstructured":"Twelves C.; Cortes J.; Vahdat L.; Olivo M.; He Y.; Kaufman P.A.; Awada A.; Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014,148(3),553-561","journal-title":"Breast Cancer Res Treat"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/0008-5472.CAN-17-1467","volume":"78","author":"Wozniak K.M.","year":"2018","unstructured":"Wozniak K.M.; Vornov J.J.; Wu Y.; Liu Y.; Carozzi V.A.; Rodriguez-Menendez V.; Ballarini E.; Alberti P.; Pozzi E.; Semperboni S.; Cook B.M.; Littlefield B.A.; Nomoto K.; Condon K.; Eckley S.; DesJardins C.; Wilson L.; Jordan M.A.; Feinstein S.C.; Cavaletti G.; Polydefkis M.; Slusher B.S.; Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery. Cancer Res 2018,78(3),817-829","journal-title":"Cancer Res"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"Okouneva T.","year":"2008","unstructured":"Okouneva T.; Azarenko O.; Wilson L.; Littlefield B.A.; Jordan M.A.; Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008,7(7),2003-2011","journal-title":"Mol Cancer Ther"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"Jordan M.A.","year":"2005","unstructured":"Jordan M.A.; Kamath K.; Manna T.; Okouneva T.; Miller H.P.; Davis C.; Littlefield B.A.; Wilson L.; The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005,4(7),1086-1095","journal-title":"Mol Cancer Ther"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/WCO.0b013e3282f1a06e","volume":"20","author":"Kannarkat G.","year":"2007","unstructured":"Kannarkat G.; Lasher E.E.; Schiff D.; Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007,20(6),719-725","journal-title":"Curr Opin Neurol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1081\/CNV-120018236","volume":"21","author":"Visovsky C.","year":"2003","unstructured":"Visovsky C.; Chemotherapy-induced peripheral neuropathy. Cancer Invest 2003,21(3),439-451","journal-title":"Cancer Invest"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","volume":"124","author":"Ansell S.M.","year":"2014","unstructured":"Ansell S.M.; Brentuximab vedotin. Blood 2014,124(22),3197-3200","journal-title":"Blood"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"Connors J.M.","year":"2018","unstructured":"Connors J.M.; Jurczak W.; Straus D.J.; Ansell S.M.; Kim W.S.; Gallamini A.; Younes A.; Alekseev S.; Ill&#xE9;s &#xC1;.; Picardi M.; Lech-Maranda E.; Oki Y.; Feldman T.; Smolewski P.; Savage K.J.; Bartlett N.L.; Walewski J.; Chen R.; Ramchandren R.; Zinzani P.L.; Cunningham D.; Rosta A.; Josephson N.C.; Song E.; Sachs J.; Liu R.; Jolin H.A.; Huebner D.; Radford J.; Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 2018,378(4),331-344","journal-title":"N Engl J Med"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"Horwitz S.","year":"2019","unstructured":"Horwitz S.; O\u2019Connor O.A.; Pro B.; Illidge T.; Fanale M.; Advani R.; Bartlett N.L.; Christensen J.H.; Morschhauser F.; Domingo-Domenech E.; Rossi G.; Kim W.S.; Feldman T.; Lennard A.; Belada D.; Ill&#xE9;s &#xC1;.; Tobinai K.; Tsukasaki K.; Yeh S.P.; Shustov A.; H&#xFC;ttmann A.; Savage K.J.; Yuen S.; Iyer S.; Zinzani P.L.; Hua Z.; Little M.; Rao S.; Woolery J.; Manley T.; Tr&#xFC;mper L.; Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019,393(10168),229-240","journal-title":"Lancet"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","volume":"19","author":"Deng C.","year":"2013","unstructured":"Deng C.; Pan B.; O\u2019Connor O.A.; Brentuximab vedotin. Clin Cancer Res 2013,19(1),22-27","journal-title":"Clin Cancer Res"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/0092-8674(93)90361-S","volume":"73","author":"Smith C.A.","year":"1993","unstructured":"Smith C.A.; Gruss H-J.; Davis T.; Anderson D.; Farrah T.; Baker E.; Sutherland G.R.; Brannan C.I.; Copeland N.G.; Jenkins N.A.; CD30 antigen, a marker for Hodgkin\u2019s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993,73(7),1349-1360","journal-title":"Cell"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"Aggarwal B.B.","year":"2012","unstructured":"Aggarwal B.B.; Gupta S.C.; Kim J.H.; Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012,119(3),651-665","journal-title":"Blood"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1074\/jbc.M510026200","volume":"281","author":"Sutherland M.S.K.","year":"2006","unstructured":"Sutherland M.S.K.; Sanderson R.J.; Gordon K.A.; Andreyka J.; Cerveny C.G.; Yu C.; Lewis T.S.; Meyer D.L.; Zabinski R.F.; Doronina S.O.; Senter P.D.; Law C.L.; Wahl A.F.; Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006,281(15),10540-10547","journal-title":"J Biol Chem"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"Okeley N.M.","year":"2010","unstructured":"Okeley N.M.; Miyamoto J.B.; Zhang X.; Sanderson R.J.; Benjamin D.R.; Sievers E.L.; Senter P.D.; Alley S.C.; Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010,16(3),888-897","journal-title":"Clin Cancer Res"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.clml.2012.01.012","volume":"12","author":"Fromm J.R.","year":"2012","unstructured":"Fromm J.R.; McEarchern J.A.; Kennedy D.; Thomas A.; Shustov A.R.; Gopal A.K.; Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk 2012,12(4),280-283","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1080\/10428194.2019.1605068","volume":"60","author":"Mariotto S.","year":"2019","unstructured":"Mariotto S.; Tecchio C.; Sorio M.; Bertolasi L.; Turatti M.; Tozzi M.C.; Benedetti F.; Cavaletti G.; Monaco S.; Ferrari S.; Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leuk Lymphoma 2019,60(11),2806-2809","journal-title":"Leuk Lymphoma"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","volume":"132","author":"Corbin Z.A.","year":"2017","unstructured":"Corbin Z.A.; Nguyen-Lin A.; Li S.; Rahbar Z.; Tavallaee M.; Vogel H.; Salva K.A.; Wood G.S.; Kim Y.H.; Nagpal S.; Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and S&#xE9;zary Syndrome. J Neurooncol 2017,132(3),439-446","journal-title":"J Neurooncol"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/cpt.1530","volume":"106","author":"Suri A.","year":"2019","unstructured":"Suri A.; Mould D.R.; Song G.; Collins G.P.; Endres C.J.; Gomez-Navarro J.; Venkatakrishnan K.; Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin\u2019s Lymphoma in the Phase III ECHELON-1 Study. Clin Pharmacol Ther 2019,106(6),1268-1279","journal-title":"Clin Pharmacol Ther"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1038\/bcj.2015.72","volume":"5","author":"Mariotto S","year":"2015","unstructured":"Mariotto S; Ferrari S; Sorio M; Benedetti F; Tridente G; Cavallaro T; Brentuximab vedotin: axonal microtubule\u2019s Apollyon. Blood cancer journal 2015,5(8),e343","journal-title":"Blood cancer journal"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2174\/138955708786369573","volume":"8","author":"McGeary R.P.","year":"2008","unstructured":"McGeary R.P.; Bennett A.J.; Tran Q.B.; Cosgrove K.L.; Ross B.P.; Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 2008,8(13),1384-1394","journal-title":"Mini Rev Med Chem"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0304-3835(79)90017-X","volume":"8","author":"De Clercq E.","year":"1979","unstructured":"De Clercq E.; Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 1979,8(1),9-22","journal-title":"Cancer Lett"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(85)90002-9","volume":"2","author":"Broder S.","year":"1985","unstructured":"Broder S.; Yarchoan R.; Collins J.M.; Lane H.C.; Markham P.D.; Klecker R.W.; Redfield R.R.; Mitsuya H.; Hoth D.F.; Gelmann E.; Effects of suramin on HTLV-III\/LAV infection presenting as Kaposi\u2019s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 1985,2(8456),627-630","journal-title":"Lancet"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/jnci\/85.8.611","volume":"85","author":"Eisenberger M.A.","year":"1993","unstructured":"Eisenberger M.A.; Reyno L.M.; Jodrell D.I.; Sinibaldi V.J.; Tkaczuk K.H.; Sridhara R.; Zuhowski E.G.; Lowitt M.H.; Jacobs S.C.; Egorin M.J.; Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993,85(8),611-621","journal-title":"J Natl Cancer Inst"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.1992.10.6.881","volume":"10","author":"Myers C.","year":"1992","unstructured":"Myers C.; Cooper M.; Stein C.; LaRocca R.; Walther M.M.; Weiss G.; Choyke P.; Dawson N.; Steinberg S.; Uhrich M.M.; Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992,10(6),881-889","journal-title":"J Clin Oncol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/brain\/119.6.2039","volume":"119","author":"Chaudhry V.","year":"1996","unstructured":"Chaudhry V.; Eisenberger M.A.; Sinibaldi V.J.; Sheikh K.; Griffin J.W.; Cornblath D.R.; A prospective study of suramin-induced peripheral neuropathy. Brain 1996,119(Pt 6),2039-2052","journal-title":"Brain"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0022-510X(01)00633-5","volume":"192","author":"Russell J.W.","year":"2001","unstructured":"Russell J.W.; Gill J.S.; Sorenson E.J.; Schultz D.A.; Windebank A.J.; Suramin-induced neuropathy in an animal model. J Neurol Sci 2001,192(1-2),71-80","journal-title":"J Neurol Sci"},{"key":"ref=188","first-page":"87","volume":"32","author":"Constantopoulos G.","year":"1981","unstructured":"Constantopoulos G.; Rees S.; Cragg B.G.; Barranger J.A.; Brady R.O.; Effect of suramin on the activities of degradative enzymes of sphingolipids in rats. Res Commun Chem Pathol Pharmacol 1981,32(1),87-97","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"Quasthoff S.","year":"2002","unstructured":"Quasthoff S.; Hartung H.P.; Chemotherapy-induced peripheral neuropathy. J Neurol 2002,249(1),9-17","journal-title":"J Neurol"},{"key":"ref=190","first-page":"177","volume":"45","author":"Voogd T.E.","year":"1993","unstructured":"Voogd T.E.; Vansterkenburg E.L.; Wilting J.; Janssen L.H.; Recent research on the biological activity of suramin. Pharmacol Rev 1993,45(2),177-203","journal-title":"Pharmacol Rev"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/00019052-200210000-00015","volume":"15","author":"Peltier A.C.","year":"2002","unstructured":"Peltier A.C.; Russell J.W.; Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002,15(5),633-638","journal-title":"Curr Opin Neurol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/sj.cdd.4400410","volume":"5","author":"Gill J.S.","year":"1998","unstructured":"Gill J.S.; Windebank A.J.; Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ 1998,5(10),876-883","journal-title":"Cell Death Differ"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1006\/exnr.1995.1014","volume":"133","author":"Gill J.S.","year":"1995","unstructured":"Gill J.S.; Hobday K.L.; Windebank A.J.; Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures. Exp Neurol 1995,133(2),113-124","journal-title":"Exp Neurol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/(SICI)1098-1136(199808)23:4<374::AID-GLIA9>3.0.CO;2-2","volume":"23","author":"Mayer C.","year":"1998","unstructured":"Mayer C.; Quasthoff S.; Grafe P.; Differences in the sensitivity to purinergic stimulation of myelinating and non-myelinating Schwann cells in peripheral human and rat nerve. Glia 1998,23(4),374-382","journal-title":"Glia"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"E346","DOI":"10.3390\/molecules23020346","volume":"23","author":"von der Ahe D.","year":"2018","unstructured":"von der Ahe D.; Huehnchen P.; Balkaya M.; Peruzzaro S.; Endres M.; Boehmerle W.; Suramin-Induced Neurotoxicity: Preclinical Models and Neuroprotective Strategies. Molecules 2018,23(2),E346","journal-title":"Molecules"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/pds.1282","volume":"16","author":"Martin K.","year":"2007","unstructured":"Martin K.; Bentaberry F.; Dumoulin C.; Miremont-Salam&#xE9; G.; Haramburu F.; Dehais J.; Schaeverbeke T.; Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf 2007,16(1),74-78","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jocn.2005.08.021","volume":"14","author":"Kho L.K.","year":"2007","unstructured":"Kho L.K.; Kermode A.G.; Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007,14(2),179-181","journal-title":"J Clin Neurosci"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1445-5994.2007.01266.x","volume":"37","author":"Richards B.L.","year":"2007","unstructured":"Richards B.L.; Spies J.; McGill N.; Richards G.W.; Vaile J.; Bleasel J.F.; Youssef P.P.; Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007,37(2),101-107","journal-title":"Intern Med J"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/ard.59.11.841","volume":"59","author":"Breedveld F.C.","year":"2000","unstructured":"Breedveld F.C.; Dayer J.M.; Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000,59(11),841-849","journal-title":"Ann Rheum Dis"},{"key":"ref=200","volume":"41","author":"Weaver A.","year":"1998","unstructured":"Weaver A.; Caldwell J.; Olsen N.; Cohen S.; Strand V.; Treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. Arthritis Rheum 1998,41(9)","journal-title":"Arthritis Rheum"},{"key":"ref=201","first-page":"1595","volume":"38","author":"Mladenovic V.","year":"1995","unstructured":"Mladenovic V.; Domljan Z.; Rozman B.; Jajic I.; Mihajlovic D.; Dordevic J.; Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis","journal-title":"Official Journal of the American College of Rheumatology"},{"key":"ref=202","author":"Weber W","year":"1998","unstructured":"Weber W; Harnisch L; Leflunomide in rheumatoid arthritis: population pharmacokinetic analysis of phase III studies. Rheumatol Eur1998 1998","journal-title":"Rheumatol Eur1998"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","volume":"44","author":"Cohen S.","year":"2001","unstructured":"Cohen S.; Cannon G.W.; Schiff M.; Weaver A.; Fox R.; Olsen N.; Furst D.; Sharp J.; Moreland L.; Caldwell J.; Kaine J.; Strand V.; Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001,44(9),1984-1992","journal-title":"Arthritis Rheum"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2165\/00003088-200241060-00003","volume":"41","author":"Rozman B.","year":"2002","unstructured":"Rozman B.; Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002,41(6),421-430","journal-title":"Clin Pharmacokinet"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.clpt.2004.01.016","volume":"75","author":"Bonnel R.A.","year":"2004","unstructured":"Bonnel R.A.; Graham D.J.; Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004,75(6),580-585","journal-title":"Clin Pharmacol Ther"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/ard.2004.027193","volume":"64","author":"Martin K.","year":"2005","unstructured":"Martin K.; Bentaberry F.; Dumoulin C.; Longy-Boursier M.; Lifermann F.; Haramburu F.; Dehais J.; Schaeverbeke T.; B&#xE9;gaud B.; Moore N.; Neuropathy associated with leflunomide: a case series. Ann Rheum Dis 2005,64(4),649-650","journal-title":"Ann Rheum Dis"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/rheumatology\/41.8.952","volume":"41","author":"Carulli M.T.","year":"2002","unstructured":"Carulli M.T.; Davies U.M.; Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology (Oxford) 2002,41(8),952-953","journal-title":"Rheumatology (Oxford)"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/bmj.1.6020.1241","volume":"1","author":"Fleming A.","year":"1976","unstructured":"Fleming A.; Dodman S.; Crown J.M.; Corbett M.; Extra-articular features in early rheumatoid disease. BMJ 1976,1(6020),1241-1243","journal-title":"BMJ"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/jnnp.33.5.592","volume":"33","author":"Weller R.O.","year":"1970","unstructured":"Weller R.O.; Bruckner F.E.; Chamberlain M.A.; Rheumatoid neuropathy: a histological and electrophysiological study. J Neurol Neurosurg Psychiatry 1970,33(5),592-604","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/art.1780260702","volume":"26","author":"Schlumpf U.","year":"1983","unstructured":"Schlumpf U.; Meyer M.; Ulrich J.; Friede R.L.; Neurologic complications induced by gold treatment. Arthritis Rheum 1983,26(7),825-831","journal-title":"Arthritis Rheum"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/bmj.2.3964.1303","volume":"2","author":"Lescher F.G.","year":"1936","unstructured":"Lescher F.G.; Nervous complications following treatment by gold salts. BMJ 1936,2(3964),1303-1305","journal-title":"BMJ"},{"key":"ref=212","author":"Sundelin FF","year":"1941","unstructured":"Sundelin FF; Die Goldbehandlung der chronischen Arthritis unter besonderer Ber&#xFC;cksichtigung der Komplikationen: aus\" Nyn&#xE4;s Kuranstalt\", Krankenhaus d. schwed. kgl. Pensionsdirektion f. Nerven-u. Rheumakranke, u. aus d. Staatl. Inst. f. menschl. Erblichkeitsforschg u. Rassenbiologie zu Uppsala: Acta Medica Skandinavica 1941"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3181\/00379727-129-33372","volume":"129","author":"Chang R.J.","year":"1968","unstructured":"Chang R.J.; Persellin R.H.; Gold thiomalate-induced weight gain in guinea pigs. Proc Soc Exp Biol Med 1968,129(2),568-571","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=214","first-page":"395","volume":"99","author":"Endtz L.J.","year":"1958","unstructured":"Endtz L.J.; Complications nerveuses du traitement aurique; aper&#xE7;u des symptomes neurologiques et psychiatriques; r&#xE9;sultats du traitement par le B.A.L. Rev Neurol (Paris) 1958,99(3),395-410","journal-title":"Rev Neurol (Paris)"},{"key":"ref=215","first-page":"475","author":"Meyer M.","year":"1978","unstructured":"Meyer M.; Haecki M.; Ziegler W.; Forster W.; Schiller H.;  Autonomic dysfunction and myokymia in gold neuropathy Peripheral Neuropathies 1978,475-480","journal-title":"Autonomic dysfunction and myokymia in gold neuropathy Peripheral Neuropathies"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1212\/WNL.20.5.455","volume":"20","author":"Walsh J.C.","year":"1970","unstructured":"Walsh J.C.; Gold neuropathy. Neurology 1970,20(5),455-458","journal-title":"Neurology"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00690533","volume":"75","author":"Tegn&#xE9;r R.","year":"1988","unstructured":"Tegn&#xE9;r R.; Tom&#xE9; F.M.; Godeau P.; Lhermitte F.; Fardeau M.; Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol 1988,75(3),253-260","journal-title":"Acta Neuropathol"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/mus.880110205","volume":"11","author":"Sghirlanzoni A.","year":"1988","unstructured":"Sghirlanzoni A.; Mantegazza R.; Mora M.; Pareyson D.; Cornelio F.; Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve 1988,11(2),114-119","journal-title":"Muscle Nerve"},{"key":"ref=219","first-page":"177","volume":"111","author":"Garcin R.","year":"1964","unstructured":"Garcin R.; Rondot P.; Fardeau M.; Sur les accidents neuromusculaires et en particulier sur une &#x201C;myopathie vacuolaire&#x201D; observ&#xE9;s au cours d\u2019un traitement prolong&#xE9; par la chloroquine. Rev Neurol (Paris) 1964,111,177-195","journal-title":"Rev Neurol (Paris)"},{"key":"ref=220","first-page":"1103","volume":"96","author":"Bonard E.C.","year":"1966","unstructured":"Bonard E.C.; Neuropathy caused by chloroquine. Schweiz Med Wochenschr 1966,96(34),1103-1105","journal-title":"Schweiz Med Wochenschr"},{"key":"ref=221","first-page":"3205","volume":"6","author":"Lhermitte F.","year":"1977","unstructured":"Lhermitte F.; Marteau R.; Chedru F.; Mallecourt J.; Estrade G.; Godet-Guillain J.; Chevallay M.; Chloroquine neuromyopathy. One case in prophylactic maleriatherapy (author\u2019s transl). Nouv Presse Med 1977,6(35),3205-3207","journal-title":"Nouv Presse Med"},{"key":"ref=222","first-page":"1697","volume":"2","author":"Victor M.","year":"1994","unstructured":"Victor M.; Myopathies due to drugs, toxins, and nutritional deficiency. Myology 1994,2,1697-1725","journal-title":"Myology"},{"key":"ref=223","author":"Whisnant J.","year":"1963","unstructured":"Whisnant J.; Espinosa R.; Kierland R.; Lambert E.; Chloroquine neuromyopathy. Proceedings of the staff meetings Mayo Clinic 1963","journal-title":"Proceedings of the staff meetings Mayo Clinic"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0022-510X(77)90149-6","volume":"34","author":"Mastaglia F.L.","year":"1977","unstructured":"Mastaglia F.L.; Papadimitriou J.M.; Dawkins R.L.; Beveridge B.; Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. Report of a case with unusual mitochondrial changes and lipid accumulation in muscle. J Neurol Sci 1977,34(3),315-328","journal-title":"J Neurol Sci"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/mus.880020509","volume":"2","author":"Neville H.E.","year":"1979","unstructured":"Neville H.E.; Maunder-Sewry C.A.; McDougall J.; Sewell J.R.; Dubowitz V.; Chloroquine-induced cytosomes with curvilinear profiles in muscle. Muscle Nerve 1979,2(5),376-381","journal-title":"Muscle Nerve"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000114244","volume":"9","author":"G&#xE9;rard J-M.","year":"1973","unstructured":"G&#xE9;rard J-M.; Stoupel N.; Collier A.; Flament-Durand J.; Morphologic study of a neuromyopathy caused by prolonged chloroquine treatment. Eur Neurol 1973,9(6),363-379","journal-title":"Eur Neurol"},{"key":"ref=227","first-page":"746","volume":"142","author":"L&#xE9;ger J.M.","year":"1986","unstructured":"L&#xE9;ger J.M.; Puifoulloux H.; Dancea S.; Hauw J.J.; Bouche P.; Rougemont D.; Laplane D.; Chloroquine neuromyopathies: 4 cases during antimalarial prevention. Rev Neurol (Paris) 1986,142(10),746-752","journal-title":"Rev Neurol (Paris)"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/019262339402200508","volume":"22","author":"Bregman C.L.","year":"1994","unstructured":"Bregman C.L.; Buroker R.A.; Hirth R.S.; Crosswell A.R.; Durham S.K.; Etoposide- and BMY-40481-induced sensory neuropathy in mice. Toxicol Pathol 1994,22(5),528-535","journal-title":"Toxicol Pathol"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","volume":"14","author":"Grisold W","year":"2012","unstructured":"Grisold W; Cavaletti G; Windebank AJ; Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncology 2012,14(suppl_4),iv45-iv54","journal-title":"Neuro-oncology"},{"key":"ref=230","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cncr.22789","volume":"110","author":"Semiglazov VF","year":"2007","unstructured":"Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor\u2010positive breast cancer. cancer 2007,110(2),244-254","journal-title":"cancer"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3816\/CBC.2008.n.043","volume":"8","author":"Nishihori T.","year":"2008","unstructured":"Nishihori T.; Choi J.; DiGiovanna M.P.; Thomson J.G.; Kohler P.C.; McGurn J.; Chung G.G.; Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clin Breast Cancer 2008,8(4),362-365","journal-title":"Clin Breast Cancer"},{"key":"ref=232","first-page":"192","volume":"58","author":"Shoults K.","year":"2016","unstructured":"Shoults K.; Case report: neurological complications of nitrous oxide abuse. BCMJ 2016,58,192-194","journal-title":"BCMJ"},{"key":"ref=233","first-page":"111","volume":"12","author":"Safari A.","year":"2013","unstructured":"Safari A.; Emadi F.; Jamali E.; Borhani-Haghighi A.; Clinical and MRI manifestations of nitrous oxide induced vitamin B12 deficiency: A case report. Iran J Neurol 2013,12(3),111-113","journal-title":"Iran J Neurol"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/archneur.1978.00500340034006","volume":"35","author":"Moddel G.","year":"1978","unstructured":"Moddel G.; Bilbao J.M.; Payne D.; Ashby P.; Disulfiram neuropathy. Arch Neurol 1978,35(10),658-660","journal-title":"Arch Neurol"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13256-016-0865-z","volume":"10","author":"Tran A.T.","year":"2016","unstructured":"Tran A.T.; Rison R.A.; Beydoun S.R.; Disulfiram neuropathy: two case reports. J Med Case Reports 2016,10(1),72","journal-title":"J Med Case Reports"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","volume":"316","author":"Kuncl R.W.","year":"1987","unstructured":"Kuncl R.W.; Duncan G.; Watson D.; Alderson K.; Rogawski M.A.; Peper M.; Colchicine myopathy and neuropathy. N Engl J Med 1987,316(25),1562-1568","journal-title":"N Engl J Med"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"291","DOI":"10.47276\/lr.91.3.291","volume":"91","author":"Shrestha S.","year":"2020","unstructured":"Shrestha S.; Chaudhary S.; Giri H.; Marahatta S.; Dapsone-induced optic atrophy: a rare case report. Lepr Rev 2020,91,291-294","journal-title":"Lepr Rev"},{"key":"ref=238","first-page":"204","volume":"5","author":"Choi S.S.","year":"1999","unstructured":"Choi S.S.; Chan K.F.; Ng H.K.; Mak W.P.; Colchicine-induced myopathy and neuropathy. Hong Kong Med J 1999,5(2),204-207","journal-title":"Hong Kong Med J"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/2042533313476692","volume":"4","author":"Wong Sh.","year":"2013","unstructured":"Wong Sh.; Silva F.; Acheson J.; Plant G.; An old friend revisited: chloramphenicol optic neuropathy. JRSM Short Rep 2013,4(3),20","journal-title":"JRSM Short Rep"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.eye.6702050","volume":"20","author":"Chalioulias K.","year":"2006","unstructured":"Chalioulias K.; Mayer E.; Darvay A.; Antcliff R.; Anterior ischaemic optic neuropathy associated with Dapsone. Eye (Lond) 2006,20(8),943-945","journal-title":"Eye (Lond)"},{"key":"ref=241","first-page":"19","volume":"3","author":"McCarty M.","year":"2010","unstructured":"McCarty M.; How clinically relevant is dapsone-related peripheral neuropathy?: an overview of available data with emphasis on clinical recognition. J Clin Aesthet Dermatol 2010,3(3),19-21","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1081\/JDI-120038521","volume":"26","author":"Fang J.T.","year":"2004","unstructured":"Fang J.T.; Chen Y.C.; Chang M.Y.; Ethambutol-induced optic neuritis in patients with end stage renal disease on hemodialysis: two case reports and literature review. Ren Fail 2004,26(2),189-193","journal-title":"Ren Fail"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/pgmj.48.565.667","volume":"48","author":"Tugwell P.","year":"1972","unstructured":"Tugwell P.; James S.L.; Peripheral neuropathy with ethambutol. Postgrad Med J 1972,48(565),667-670","journal-title":"Postgrad Med J"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"bcr-2017","DOI":"10.1136\/bcr-2017-223187","volume":"2018","author":"Si M.","year":"2018","unstructured":"Si M.; Li H.; Chen Y.; Peng H.; Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. BMJ Case Rep 2018,2018,bcr-2017-bcr-223187","journal-title":"BMJ Case Rep"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1345\/aph.1Z429","volume":"35","author":"Cohen J.S.","year":"2001","unstructured":"Cohen J.S.; Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001,35(12),1540-1547","journal-title":"Ann Pharmacother"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000489303","volume":"10","author":"Popescu C.","year":"2018","unstructured":"Popescu C.; Severe acute axonal neuropathy induced by ciprofloxacin: a case report. Case Rep Neurol 2018,10(2),124-129","journal-title":"Case Rep Neurol"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archneurol.2011.1120","volume":"69","author":"Tan I.L.","year":"2012","unstructured":"Tan I.L.; Polydefkis M.J.; Ebenezer G.J.; Hauer P.; McArthur J.C.; Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012,69(2),265-268","journal-title":"Arch Neurol"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1212\/WNL.23.5.554","volume":"23","author":"Toole J.F.","year":"1973","unstructured":"Toole J.F.; Parrish M.L.; Nitrofurantoin polyneuropathy. Neurology 1973,23(5),554-559","journal-title":"Neurology"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s10072-015-2260-8","volume":"36","author":"Ca&#xE7;&#xE3;o G.","year":"2015","unstructured":"Ca&#xE7;&#xE3;o G.; Fontes S.; Salgado M.; Rodrigues T.; Dam&#xE1;sio J.; Metronidazole-induced central and peripheral nervous system toxicity. Neurol Sci 2015,36(9),1737-1739","journal-title":"Neurol Sci"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/0301-4738.77035","volume":"59","author":"Sharma P.","year":"2011","unstructured":"Sharma P.; Sharma R.; Toxic optic neuropathy. Indian J Ophthalmol 2011,59(2),137-141","journal-title":"Indian J Ophthalmol"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40560-017-0257-5","volume":"5","author":"Zaworski J.","year":"2017","unstructured":"Zaworski J.; Delannoy P-Y.; Boussekey N.; Thellier D.; Georges H.; Leroy O.; Lithium: one drug, five complications. J Intensive Care 2017,5(1),70","journal-title":"J Intensive Care"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp.45.7.620","volume":"45","author":"Shorvon S.D.","year":"1982","unstructured":"Shorvon S.D.; Reynolds E.H.; Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J Neurol Neurosurg Psychiatry 1982,45(7),620-626","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jama.1958.02990210013003","volume":"167","author":"Kirkendall W.M.","year":"1958","unstructured":"Kirkendall W.M.; Page E.B.; Polyneuritis occurring during hydralazine therapy; report of two cases and discussion of adverse reactions to hydralazine. J Am Med Assoc 1958,167(4),427-432","journal-title":"J Am Med Assoc"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2125.1981.tb01181.x","volume":"11","author":"Tsujimoto G.","year":"1981","unstructured":"Tsujimoto G.; Horai Y.; Ishizaki T.; Itoh K.; Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient. Br J Clin Pharmacol 1981,11(6),622-625","journal-title":"Br J Clin Pharmacol"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jpain.2014.06.012","volume":"15","author":"Bhalla S.","year":"2014","unstructured":"Bhalla S.; Singh N.; Jaggi A.S.; Statins: do they aggravate or ameliorate neuropathic pain? J Pain 2014,15(11),1069-1080","journal-title":"J Pain"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.19082\/6527","volume":"10","author":"Emad M.","year":"2018","unstructured":"Emad M.; Arjmand H.; Farpour H.R.; Kardeh B.; Lipid-lowering drugs (statins) and peripheral neuropathy. Electron Physician 2018,10(3),6527-6533","journal-title":"Electron Physician"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1212\/WNL.50.3.824","volume":"50","author":"Erdem S.","year":"1998","unstructured":"Erdem S.; Freimer M.L.; O\u2019Dorisio T.; Mendell J.R.; Procainamide-induced chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1998,50(3),824-825","journal-title":"Neurology"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"17549","DOI":"10.1038\/s41598-019-54152-8","volume":"9","author":"Hooijmans C.R.","year":"2019","unstructured":"Hooijmans C.R.; Draper D.; Erg&#xFC;n M.; Scheffer G.J.; The effect of analgesics on stimulus evoked pain-like behaviour in animal models for chemotherapy induced peripheral neuropathy- a meta-analysis. Sci Rep 2019,9(1),17549","journal-title":"Sci Rep"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/00000542-200203000-00020","volume":"96","author":"Matthews E.A.","year":"2002","unstructured":"Matthews E.A.; Dickenson A.H.; A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology 2002,96(3),633-640","journal-title":"Anesthesiology"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1017\/S0317167100004236","volume":"32","author":"Moulin D.E.","year":"2005","unstructured":"Moulin D.E.; Palma D.; Watling C.; Schulz V.; Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci 2005,32(3),340-343","journal-title":"Can J Neurol Sci"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5055\/jom.2006.0040","volume":"2","author":"Mannino R.","year":"2006","unstructured":"Mannino R.; Coyne P.; Swainey C.; Hansen L.A.; Lyckholm L.; Methadone for cancer-related neuropathic pain: a review of the literature. J Opioid Manag 2006,2(5),269-276","journal-title":"J Opioid Manag"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","volume":"6","author":"Rahn E.J.","year":"2009","unstructured":"Rahn E.J.; Hohmann A.G.; Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009,6(4),713-737","journal-title":"Neurotherapeutics"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40122-017-0091-4","volume":"6","author":"Fornasari D.","year":"2017","unstructured":"Fornasari D.; Pharmacotherapy for neuropathic pain: a review. Pain Ther 2017,6(1)(Suppl. 1),25-33","journal-title":"Pain Ther"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-7843.2005.pto_96696601.x","volume":"96","author":"Sindrup S.H.","year":"2005","unstructured":"Sindrup S.H.; Otto M.; Finnerup N.B.; Jensen T.S.; Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005,96(6),399-409","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0091270010394852","volume":"52","author":"Dharmshaktu P.","year":"2012","unstructured":"Dharmshaktu P.; Tayal V.; Kalra B.S.; Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012,52(1),6-17","journal-title":"J Clin Pharmacol"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1517\/14656566.2010.507192","volume":"11","author":"Lee Y-C.","year":"2010","unstructured":"Lee Y-C.; Chen P-P.; A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 2010,11(17),2813-2825","journal-title":"Expert Opin Pharmacother"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","volume":"73","author":"Taylor C.P.","year":"2007","unstructured":"Taylor C.P.; Angelotti T.; Fauman E.; Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007,73(2),137-150","journal-title":"Epilepsy Res"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/j.pain.0000000000001577","volume":"160","author":"Hincker A.","year":"2019","unstructured":"Hincker A.; Frey K.; Rao L.; Wagner-Johnston N.; Ben Abdallah A.; Tan B.; Amin M.; Wildes T.; Shah R.; Karlsson P.; Bakos K.; Kosicka K.; Kagan L.; Haroutounian S.; Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain 2019,160(8),1835-1846","journal-title":"Pain"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1188\/07.CJON.901-913","volume":"11","author":"Visovsky C.","year":"2007","unstructured":"Visovsky C.; Collins M.; Abbott L.; Aschenbrenner J.; Hart C.; Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2007,11(6),901-913","journal-title":"Clin J Oncol Nurs"},{"key":"ref=270","author":"Bandla A.","year":"2020","unstructured":"Bandla A.; Santhanakrishnan P.; Magarajah G.; Vaidya G.A.; Subramanian A.; Wei H.; Limb Hypothermia for the Prevention of Chemotherapy-Induced Peripheral Neuropathy-Modality for Optimal Cooling. 42nd Annual International Conference of the IEEE Engineering in Medicine  2020","journal-title":"42nd Annual International Conference of the IEEE Engineering in Medicine"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/0284186X.2012.658966","volume":"51","author":"van den Hurk C.J.","year":"2012","unstructured":"van den Hurk C.J.; Peerbooms M.; van de Poll-Franse L.V.; Nortier J.W.; Coebergh J.W.W.; Breed W.P.; Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 2012,51(4),497-504","journal-title":"Acta Oncol"},{"key":"ref=272","first-page":"343","volume":"42","author":"Kennet J.","year":"2007","unstructured":"Kennet J.; Hardaker N.; Hobbs S.; Selfe J.; Cooling efficiency of 4 common cryotherapeutic agents. J Athl Train 2007,42(3),343-348","journal-title":"J Athl Train"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.apmr.2004.11.034","volume":"86","author":"Kanlayanaphotporn R.","year":"2005","unstructured":"Kanlayanaphotporn R.; Janwantanakul P.; Comparison of skin surface temperature during the application of various cryotherapy modalities. Arch Phys Med Rehabil 2005,86(7),1411-1415","journal-title":"Arch Phys Med Rehabil"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/jnci\/djx178","volume":"110","author":"Hanai A.","year":"2018","unstructured":"Hanai A.; Ishiguro H.; Sozu T.; Tsuda M.; Yano I.; Nakagawa T.; Imai S.; Hamabe Y.; Toi M.; Arai H.; Tsuboyama T.; Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. JNCI. J Natl Cancer Inst 2018,110(2),141-148","journal-title":"J Natl Cancer Inst"},{"key":"ref=275","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-013-2728-2","volume":"142","author":"Eckhoff L.","year":"2013","unstructured":"Eckhoff L.; Knoop A.S.; Jensen M-B.; Ejlertsen B.; Ewertz M.; Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 2013,142(1),109-118","journal-title":"Breast Cancer Res Treat"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/cncr.23333","volume":"112","author":"Scott&#xE9; F.","year":"2008","unstructured":"Scott&#xE9; F.; Banu E.; Medioni J.; Levy E.; Ebenezer C.; Marsan S.; Banu A.; Tourani J.M.; Andrieu J.M.; Oudard S.; Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008,112(7),1625-1631","journal-title":"Cancer"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.breast.2019.12.011","volume":"49","author":"Kanbayashi Y.","year":"2020","unstructured":"Kanbayashi Y.; Sakaguchi K.; Ishikawa T.; Ouchi Y.; Nakatsukasa K.; Tabuchi Y.; Kanehisa F.; Hiramatsu M.; Takagi R.; Yokota I.; Katoh N.; Taguchi T.; Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial. Breast 2020,49,219-224","journal-title":"Breast"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0749-8063(98)70030-1","volume":"14","author":"Barber F.A.","year":"1998","unstructured":"Barber F.A.; McGuire D.A.; Click S.; Continuous-flow cold therapy for outpatient anterior cruciate ligament reconstruction. Arthroscopy 1998,14(2),130-135","journal-title":"Arthroscopy"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.otsr.2013.12.019","volume":"100","author":"Murgier J.","year":"2014","unstructured":"Murgier J.; Cassard X.; Cryotherapy with dynamic intermittent compression for analgesia after anterior cruciate ligament reconstruction. Preliminary study. Orthop Traumatol Surg Res 2014,100(3),309-312","journal-title":"Orthop Traumatol Surg Res"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fonc.2016.00274","volume":"6","author":"Sundar R.","year":"2017","unstructured":"Sundar R.; Bandla A.; Tan S.S.H.; Liao L-D.; Kumarakulasinghe N.B.; Jeyasekharan A.D.; Ow S.G.; Ho J.; Tan D.S.; Lim J.S.; Vijayan J.; Therimadasamy A.K.; Hairom Z.; Ang E.; Ang S.; Thakor N.V.; Lee S.C.; Wilder-Smith E.P.; Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a pilot study. Front Oncol 2017,6,274","journal-title":"Front Oncol"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"1534735420943287","DOI":"10.1177\/1534735420943287","volume":"19","author":"Oneda E.","year":"2020","unstructured":"Oneda E.; Meriggi F.; Zanotti L.; Zaina E.; Bigh&#xE8; S.; Andreis F.; Rueda S.; Zaniboni A.; Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience. Integr Cancer Ther 2020,19,1534735420943287","journal-title":"Integr Cancer Ther"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14737175.2020.1796639","volume":"20","author":"Argyriou A.A.","year":"2020","unstructured":"Argyriou A.A.; Bruna J.; Park S.B.; Cavaletti G.; Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Rev Neurother 2020,20(10),1005-1016","journal-title":"Expert Rev Neurother"},{"key":"ref=283","author":"Chen M.","year":"2020","unstructured":"Chen M.;  Interactions between multi-kinase inhibitors and solute carrier transporters 2020","journal-title":"Interactions between multi-kinase inhibitors and solute carrier transporters"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.drudis.2014.11.008","volume":"20","author":"Karlsson J.O.G.","year":"2015","unstructured":"Karlsson J.O.G.; Ignarro L.J.; Lundstr&#xF6;m I.; Jynge P.; Alm&#xE9;n T.; Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discov Today 2015,20(4),411-421","journal-title":"Drug Discov Today"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ebiom.2019.07.013","volume":"46","author":"Morrison E.E.","year":"2019","unstructured":"Morrison E.E.; Oatey K.; Gallagher B.; Grahamslaw J.; O\u2019Brien R.; Black P.; Oosthuyzen W.; Lee R.J.; Weir C.J.; Henriksen D.; Dear J.W.; Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12&#x202F;h regimen of N-acetylcysteine for paracetamol overdose (POP trial). EBioMedicine 2019,46,423-430","journal-title":"EBioMedicine"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"H542","DOI":"10.1152\/ajpheart.00844.2012","volume":"305","author":"Shinbo T.","year":"2013","unstructured":"Shinbo T.; Kokubo K.; Sato Y.; Hagiri S.; Hataishi R.; Hirose M.; Kobayashi H.; Breathing nitric oxide plus hydrogen gas reduces ischemia-reperfusion injury and nitrotyrosine production in murine heart. Am J Physiol Heart Circ Physiol 2013,305(4),H542-H550","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"6295","DOI":"10.1158\/1078-0432.CCR-18-2152","volume":"25","author":"Hu S.","year":"2019","unstructured":"Hu S.; Huang K.M.; Adams E.J.; Loprinzi C.L.; Lustberg M.B.; Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2019,25(21),6295-6301","journal-title":"Clin Cancer Res"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"2058738419838383","DOI":"10.1177\/2058738419838383","volume":"33","author":"Cavalli E.","year":"2019","unstructured":"Cavalli E.; Mammana S.; Nicoletti F.; Bramanti P.; Mazzon E.; The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol 2019,33,2058738419838383","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1124\/jpet.117.243972","volume":"364","author":"Kyte S.L.","year":"2018","unstructured":"Kyte S.L.; Toma W.; Bagdas D.; Meade J.A.; Schurman L.D.; Lichtman A.H.; Chen Z.J.; Del Fabbro E.; Fang X.; Bigbee J.W.; Damaj M.I.; Gewirtz D.A.; Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. J Pharmacol Exp Ther 2018,364(1),110-119","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009621666210720142542","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194936\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009621666210720142542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T07:27:20Z","timestamp":1654759640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194936\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":289,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009621666210720142542","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}